Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EBITDA (2022 - 2025)

Corvus Pharmaceuticals has reported EBITDA over the past 4 years, most recently at -$12.2 million for Q4 2025.

  • Quarterly results put EBITDA at -$12.2 million for Q4 2025, up 4.0% from a year ago — trailing twelve months through Dec 2025 was -$14.9 million (up 76.22% YoY), and the annual figure for FY2025 was -$14.9 million, up 76.22%.
  • EBITDA for Q4 2025 was -$12.2 million at Corvus Pharmaceuticals, down from -$10.1 million in the prior quarter.
  • Over the last five years, EBITDA for CRVS hit a ceiling of $15.2 million in Q1 2025 and a floor of -$39.6 million in Q3 2024.
  • Median EBITDA over the past 4 years was -$8.0 million (2022), compared with a mean of -$9.3 million.
  • Biggest five-year swings in EBITDA: plummeted 551.85% in 2024 and later soared 353.4% in 2025.
  • Corvus Pharmaceuticals' EBITDA stood at -$9.2 million in 2022, then skyrocketed by 32.76% to -$6.2 million in 2023, then plummeted by 105.0% to -$12.7 million in 2024, then grew by 4.0% to -$12.2 million in 2025.
  • The last three reported values for EBITDA were -$12.2 million (Q4 2025), -$10.1 million (Q3 2025), and -$7.9 million (Q2 2025) per Business Quant data.